Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

24 Sep 2016

• By Derrick Gingery

PillChart_1200x675

Related Content

ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

27 Jul 2015

Generic Drugs 2014: OGD Creates Internal Review Goals, May Make OND-Inspired Changes

06 Jan 2014

Could Drug Price Spikes Spur ANDA Priority Reviews?

28 Jan 2016

FDA To ANDA Sponsors: Don't Forget Quality When Rushing For 10-Month Review Goal

17 May 2016

Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact

21 Mar 2016

GDUFA II: Priority Reviews Considered For Some ANDAs

06 Nov 2015

Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul

17 Sep 2016

EpiPen Price Hearing: House Plays Bootleg Tape Of Shkreli Event

22 Sep 2016

Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances

22 Sep 2016

EpiPen Generics: Woodcock Explains Injector Studies

22 Sep 2016

ANDA Approvals, Submissions Decline With New Review Goal Coming

12 Aug 2016

Related Companies

Vyera Pharmaceuticals, LLC

Viatris Inc.

Additional Topics

United States Drug Approval Standards Drug Review Regulation BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.